|Day's Range||1.2800 - 1.2800|
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.